A next-generation ink for endoscopic tattooing of the colon diffuses less and is more “biocompatible” than existing inks, which could help identify complex colonic polyps or tumors for removal. (American Chemical Society)
Positive topline data from a phase III study showed etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, achieved improvements in clinical remission for patients with moderate to severe active ulcerative colitis (UC), drugmaker Pfizer announced.